This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2024 Sep 1;10(9):1219-1220.

doi: 10.1001/jamaoncol.2024.0993.

Immunotherapy Before Chemoradiotherapy-More Is Better?

Narjust Florez^{1

2

3}

Affiliations

Affiliations

¹ Dana-Farber Cancer Institute, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.
³ Associate Editor for Diversity, Equity, and Inclusion, JAMA Oncology.

PMID: 39052302
DOI: 10.1001/jamaoncol.2024.0993

Immunotherapy Before Chemoradiotherapy-More Is Better?

Narjust Florez. JAMA Oncol. 2024.

. 2024 Sep 1;10(9):1219-1220.

doi: 10.1001/jamaoncol.2024.0993.

Author

Narjust Florez^{1

2

3}

Affiliations

¹ Dana-Farber Cancer Institute, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.
³ Associate Editor for Diversity, Equity, and Inclusion, JAMA Oncology.

PMID: 39052302
DOI: 10.1001/jamaoncol.2024.0993

No abstract available

PubMed Disclaimer

Comment in

Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
Ross HJ, Kozono D, Wang XF, Urbanic JJ, Williams TM, Nelson GD, Carbone DP, Chung D, Robb R, Byun WY, Talabere T, DuFrane C, Bara I, Schulze K, Brockman M, Gao J, Vokes EE, Stinchcombe TE. Ross HJ, et al. JAMA Oncol. 2024 Sep 1;10(9):1212-1219. doi: 10.1001/jamaoncol.2024.1897. JAMA Oncol. 2024. PMID: 39052256 Free PMC article. Clinical Trial.

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems